Ma Songjiang's Form 4 filing
Gyre Therapeutics, Inc. (GYRE) · filed Dec 19, 2024
- Accession no.
- 0001140361-24-049939
- Filed
- Dec 19, 2024
- Trade date
- Dec 17-18, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $44.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ma SongjiangCIK 0001985547 | Director, Officer (President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 17, 2024 | Common Stock | SSaleDisposed | −1,212 | $10.94 | −$13,259.28 | 2,941,255 | Indirect | |
| Dec 17, 2024 | Common Stock | SSaleDisposed | −788 | $11.23 | −$8,849.24 | 2,940,467 | Indirect | |
| Dec 18, 2024 | Common Stock | SSaleDisposed | −1,571 | $11.17 | −$17,548.07 | 2,938,896 | Indirect | |
| Dec 18, 2024 | Common Stock | SSaleDisposed | −429 | $12.11 | −$5,195.19 | 2,938,467 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.